SEC Form PRE 14A filed by Relmada Therapeutics Inc.
$RLMD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/24/2026 | $12.00 | Overweight | Piper Sandler |
| 1/23/2026 | $8.00 | Outperform | Leerink Partners |
| 12/22/2025 | $69.00 | Buy | Jefferies |
| 11/19/2025 | $10.00 | Neutral → Outperform | Mizuho |
| 12/5/2024 | $23.00 → $1.00 | Outperform → Neutral | Mizuho |
| 9/17/2024 | $3.50 → $13.00 | Hold → Buy | Jefferies |
| 6/5/2024 | $3.00 → $2.00 | Neutral → Sell | Goldman |
| 10/14/2022 | $81.00 → $8.00 | Buy → Neutral | Goldman |
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026. Jefferies Global Healthcare Conference DetailsFormat: Fireside ChatDate: Thursday, June 4, 2026Time: 12:50 PM ETWebcast: Click Here Management will also be available for one-on-one investor meetings during the conference. Please co
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would ha
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress. Conference Call and Webcast Information: Date: Tuesday, May 12, 2026 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Webcast Access: Click Here A replay of the webcast will be available in the
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
Piper Sandler initiated coverage of Relmada Therapeutics with a rating of Overweight and set a new price target of $12.00
Leerink Partners resumed coverage of Relmada Therapeutics with a rating of Outperform and set a new price target of $8.00
Jefferies initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $69.00
8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
S-3ASR - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
SCHEDULE 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to Relmada's Clinical Advisory Board (CAB) to support the development of NDV-01 for the
Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). Dr. Lotan's deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepa
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its Board of Directors, effective June 25, 2025. Dr. Traversa currently serves as CEO of Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions, where he has led the company through the advancement of multiple clinical-stage programs and financing events. "We're excited to welcome Sergio to the DIMERx team," said Nikhi
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would ha
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress. Conference Call and Webcast Information: Date: Tuesday, May 12, 2026 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Webcast Access: Click Here A replay of the webcast will be available in the
Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profileCompleted an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 developmentOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including comple